ABT
Abbott Laboratories
101.30$
+0.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.8% | 32.2% | 48.7% | 26.4% | 21.8% | 23.1% | 28.2% | 32.2% | 33.9% | 31.0% | 29.1% | 30.0% | |
| 9.3% | 11.4% | 33.8% | 12.3% | 5.7% | 5.7% | 9.4% | 13.0% | 13.3% | 9.4% | 9.4% | 9.8% | |
| 10.2% | 13.9% | 34.1% | 12.6% | 6.1% | 6.1% | 9.9% | 13.6% | 13.7% | 9.9% | 9.8% | 10.3% | |
| 8.2% | 7.8% | 5.9% | 6.9% | 7.7% | 8.0% | 8.8% | 8.6% | 8.4% | 9.0% | 8.5% | 9.1% | |
| 6.0% | 5.9% | 4.4% | 4.7% | 5.7% | 6.4% | 6.9% | 6.9% | 8.3% | 9.0% | 7.6% | 7.5% | |
| 13.6% | 13.0% | 10.4% | 10.0% | 11.3% | 11.8% | 12.4% | 11.9% | 12.3% | 15.4% | 14.4% | 14.9% | |
| 23.0% | 21.9% | 14.0% | 31.5% | 34.6% | 34.2% | 32.7% | 30.9% | 30.6% | 32.3% | 28.4% | 27.7% | |
| 14.2% | 12.6% | 8.3% | 28.2% | 28.2% | 25.1% | 20.4% | 16.9% | 14.0% | 12.0% | 8.2% | 6.4% | |
| 44.8% | 45.3% | 58.1% | 59.2% | 54.3% | 53.9% | 54.5% | 52.1% | 50.4% | 47.0% | 41.2% | 39.1% | |
| 24.1% | 20.9% | 12.1% | 11.7% | 13.4% | 16.0% | 16.4% | 17.4% | 20.8% | 18.9% | 17.4% | 19.0% | |
| 10.1% | 7.1% | 2.4% | 0.9% | 0.3% | 2.5% | 0.6% | 1.3% | 3.3% | 1.8% | 2.2% | 3.8% | |
| 2.4% | 2.5% | 2.1% | 3.2% | 4.4% | 4.8% | 5.4% | 5.9% | 6.2% | 5.9% | 5.2% | 4.9% | |
| 7.8% | 13.3% | 37.6% | 35.7% | 28.8% | 24.5% | 25.5% | 23.0% | 19.5% | 18.6% | 15.5% | 11.4% | |
| 49.2% | 48.2% | 37.3% | 40.5% | 45.4% | 45.8% | 45.2% | 47.6% | 49.3% | 52.7% | 58.5% | 60.1% | |
| 52.2% | 58.5% | 46.5% | 31.4% | 36.6% | 38.1% | 38.1% | 41.9% | 47.4% | 51.3% | 58.1% | 57.4% | |
| 3.5% | 3.4% | 2.7% | 2.3% | 2.6% | 2.6% | 2.5% | 2.4% | 2.4% | 2.4% | 2.1% | 2.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.